There are several reasons we are excited about Koios Medical. Firstly, the issue of false-positive breast biopsies is an incredibly traumatic experience for patients and is far too common in today’s medical landscape. Even more frightening is that there are over 130,000 missed breast cancer diagnoses per year. Today, diagnosing breast and thyroid cancer through ultrasound images is a challenging task, often not performed as well or efficiently as it should be considering available technology. Is essentially complete guesswork from doctors. Koios is a first-mover to incorporate Artificial Intelligence into the cancer diagnosis process. Koios has a massive database (2M+) of images, many of which are confirmed cancer cases. Clinicians can now compare new patient images against this database to provide far more accurate diagnoses for cancer patients. This is a massive step forward for the medical community, that is notoriously resistant to novel technologies. With no competitors, Koios is already in 500+ hospitals and outpatient clinics like Mount Sinai, Massachusetts General Hospital and Yale Hospital. Overall, we are very excited about Koios Medical’s growth prospects and particularly impressed with its execution in gaining considerable traction with some of the world's most well-known distributors. At its current valuation, we believe this is a great entry point for KC Capital, and we are excited to join Koios Medical on its journey to revolutionizing cancer diagnoses with artificial intelligence.